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Abstract
Background: Paroxysmal dyskinesias (PDs) are a group of central nervous system
diseases characterized by episodes of abnormal involuntary hyperkinetic movement
without altered consciousness that increasingly have been recognized in dogs.
Objectives: To present the phenotypical characterization, treatment, and outcome of
a PD observed in Maltese dogs.
Animals: Client-owned Maltese dogs (n = 19) with presumed diagnosis of PD.
Methods: Data were collected retrospectively from medical records (2014-2019),
and supporting information was added prospectively by using a questionnaire
directed to the owners of the affected dogs.
Results: The episodes were characterized mainly by sudden dystonia of !1 limbs and
generalized body tremors with preserved consciousness. The mean age of clinical
onset was 5.4 years. Episode frequency varied widely both among and within individ-
uals. Median episode duration was 4.5 minutes. Most episodes were stress- or
exercise-induced. Acetazolamide was administered to 6 dogs, and 4 dogs experi-
enced a decrease in episode frequency. In 7 dogs that received a gluten-free diet,
6 dogs became episode-free. In 4 dogs, the episodes stopped spontaneously and in
2 dogs no medication or specific diet was given and the episodes continued at the
same frequency.
Conclusions and Clinical Importance: Given the breed predisposition and regional
distribution of the disease, additional research should focus on elucidating the under-
lying genetic cause doing so might advance both our understanding of the patho-
physiology and treatment of this disease, not only in dogs, but also in humans.
Regardless of the treatment protocol selected, prognosis appears fair to good.
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1 | INTRODUCTION
Paroxysmal dyskinesias (PDs) are a heterogeneous group of hyperki-
netic and recurrent episodes of abnormal involuntary movement that
are self-limiting. Usually, autonomic signs are absent, consciousness is
not impaired, and abnormal postictal behavior is not observed.1 Epi-
sodes can last from seconds to minutes or even hours, and the move-
ment disturbance begins and stops abruptly. These features aid in
distinguishing PDs from epileptic seizures, the most important differ-
ential diagnosis for this condition.1
Although PDs remain poorly characterized in the veterinary litera-
ture, they have become an increasingly recognized condition over the
last decade, especially because of the fact that smartphone technol-
ogy has enabled dog owners to record episodes at home and show
them to their veterinarians.2-10
In human medicine, PDs can be classified clinically in 3 major
categories, including paroxysmal kinesigenic dyskinesia (usually brief
[<2 minutes] episodes typically precipitated by sudden movements,
which can be exacerbated by stress, menses, cold, and heat), parox-
ysmal nonkinesigenic dyskinesia (PNKD; episodes of involuntary
movements that occur spontaneously, lasting minutes to hours) and
paroxysmal exertion-induced dyskinesia (episodes induced by pro-
longed sustained exercise, lasting between seconds to 30 minutes).11
Most PDs described in dogs resemble PNKD in humans but, a recent
study proposed a clinical classification in veterinary medicine, includ-
ing genetic, secondary (eg, drug-induced PD and structural intracra-
nial disease), dietary, and unidentified (presumed genetic) causes.1
Until now, genetic sequencing has identified 2 causative genetic
mutations related to PD in dogs: episodic falling syndrome in Cava-
lier King Charles Spaniels, resulting from a mutation in the brevican
gene (BCAN)12,13 and PD in soft-coated Wheaten Terriers, which
has been associated with a mutation in the PIGN gene.10 Paroxysmal
gluten-sensitive dyskinesia is a well-described type of PNKD in Bor-
der Terriers, characterized by episodes of difficulty walking,
tremors, and dystonia of the limbs, head, and neck, and gastrointes-
tinal signs that can be observed between episodes and that improve
when a gluten-free diet is fed.3,8,14,15 For unidentified (presumed
genetic) causes, a PNKD has been described in Chinook dogs and is
characterized by an inability to stand, head tremors and involuntary
flexion of !1 limbs.2 In addition, “Scottie cramp,” an exercise-, stress-,
or excitement-induced PD in Scottish Terriers, likely also has a genetic
basis.16,17
The natural course of PDs was self-limiting in Labrador Retrievers
and Jack Russell Terriers, with 32% of the dogs undergoing spontane-
ous remission and 75% showing marked improvement.18 Several drugs
have been reported to be successful in the treatment of dogs with PD,
including acetazolamide,19fluoxetine,20clonazepam,21diazepam,22 and
phenobarbital.23
To the our knowledge, only a single abstract (from our research
group) has described this condition in Maltese dogs.24 Therefore, the
aim of our retrospective study was to describe in detail the clinical
features of this paroxysmal movement disturbance, including its treat-
ment and outcome in Maltese dogs.
2 | MATERIALS AND METHODS
Clinical cases were identified by retrospectively searching the medical
records of the Small Animal Teaching Hospital at Ghent University
between 20 June 2014 and 6 November 2019 for Maltese dogs that
were presented for evaluation of episodes of involuntary movements
without loss of consciousness and for which video footage, a detailed
description of the episodes or both were available. After inclusion,
owners were contacted by email or telephone or both and were
invited to complete a detailed questionnaire based on previous veteri-
nary literature on movement disorders in dogs. The questionnaire
contained information about age of onset, time period of occurrence,
triggers, frequency, duration, and phenotypical characterization of the
episodes (Supporting Information Addendum 1). Signalment, history,
clinical and neurological examination findings, CBC, serum biochemis-
try profile, brain magnetic resonance imaging (MRI) findings, cerebro-
spinal fluid (CSF) analysis, electrodiagnostic examination, and genetic
testing were obtained from the medical records.
2.1 | Statistical analysis
Statistical analysis was conducted by R version 3.5.2 (“Eggshell Igloo”).
When normally distributed, data are presented as mean and SD.
Otherwise, median and range are given. The relative risk and its 95%
confidence interval (CI) of the Maltese dog breed relative to the
general population of dogs presented at the Small Animal Teaching
Hospital at Ghent University during the same time period, was calcu-
lated. Significance was set at ! " .05.
3 | RESULTS
From 4428 patients that visited the neurology unit of the Small Ani-
mal Teaching Hospital at Ghent University, 19 of 125 Maltese dogs
were presented for evaluation of PD (prevalence, 15.2%), whereas
only 62 other cases of PD were identified in the remaining 4303 dogs
(prevalence, 1.4%). This difference was significant, with a relative risk
estimate for Maltese dogs relative to the general population being
equal to 9.4 (95% CI, 5.7-15.7; P < .001).
Fifteen dogs were male (9 neutered) and 4 were female (3 neutered).
The reported age of clinical onset ranged from 1 to 11 years (mean,
5.4 years). None of the dogs had a pedigree or any recorded ancestry or
lineage. In 15 dogs (79%), the episodes could be witnessed and analyzed
using a video recording provided by the owners, and in 4 dogs (21%), a
detailed description of the episodes was available. Most of the dogs
(14) were receiving commercial dog food at the time of clinical onset,
4 dogs were receiving a hypoallergenic diet (not gluten-free) and 1 dog
was receiving natural homemade food. In 7 dogs (37%), concomitant
health issues were present at the time the episodes started. One dog
had signs of inflammatory bowel disease, 2 dogs had sporadic episodes
of vomiting and borborygmi, 3 dogs suffered from skin allergy, and 1 dog
had intermittent episodes of diarrhea and skin allergy. Of the 4 dogs with
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skin problems, 1 was receiving dexamethasone (Rapidexon, Dechra,
Shrewsbury, UK) at the time the episodes started, and another dog was
receiving oclacitinib maleate (Apoquel, Zoetis, Parsippany, New Jersey),
both as treatment for the skin allergy. There was no known family history
of PD in any of the affected Maltese dogs.
3.1 | Occurrence of episodes
The episodes occurred randomly (after stress or exercise or both or at
rest) in 8 dogs (42%). In 5 dogs (26%), the episodes only occurred after
stress or exercise or both and, in 6 dogs (32%), only during rest or
sleep. The frequency of occurrence of the episodes was variable,
among and within dogs. Episodes could occur daily in the same dog,
resembling clusters, with some quiescence of weeks or months and
other dogs would experience larger intervals between episodes with-
out an evident pattern. The episodes could occur at any time during
the day in 16 dogs (84%), only in the morning in 2 dogs (10%) and only
in the evening in 1 dog. Most dogs only had 1 episode per day
(11 dogs; 58%), but 3 dogs (16%) could have up to 2 episodes per day,
1 dog up to 3 per day and in 4 dogs (21%) up to 4 times per day.
3.2 | Characterization of the episodes
Video S1 illustrates the typical clinical features of an episode. The epi-
sode starts immediately after the dog seeks the owner's attention.
The dog seems restless while generalized body tremors are evident,
and starts showing dystonia in the left thoracic limb, which progres-
sively involves all 4 limbs after adopting sternal or lateral recumbency.
The dog remains conscious during the entire episode. The clinical
signs disappear gradually and spontaneously over the course of approx-
imately 4 minutes.
Most of the owners were not able to predict the occurrence of
the episodes (10 dogs; 53%), but some dogs would seek their owners'
attention (8 dogs; 42%) or were fearful (1 dog) immediately before an
episode. All owners reported that their dogs were conscious and
aware during the episodes, being able to respond when called by their
name, although the episodes could not be stopped when the dog was
distracted by touching or calling its name. All owners described
dystonia-like disturbances (stiffness and cramping of !1 muscle
groups) in at least 1 of the limbs during the episodes (only pelvic limbs
in 6 dogs [32%], all limbs in 7 dogs [37%], only thoracic limbs in 3 dogs
[16%], or randomly 1 limb in 3 dogs [16%]). All owners described gen-
eralized body tremors (including trunk and head) and difficulty in
walking when attempted by the dog. In 9 dogs (48%), a lateral body
posture was adopted during the episodes, whereas 5 dogs (26%)
adopted a sternal position and the other 5 (26%) were in standing
position. A kyphotic posture was seen in 3 dogs (16%). Only 5 dogs
(26%) adopted salivation during the episodes, of which 2 (10%) also
had single episodes of vomiting. All dogs were clinically and neurologi-
cally normal before and between the episodes, but 3 dogs (16%)
showed a short period (<2 minutes) of fatigue and panting after the
episode occurred, and 1 dog was disoriented for approximately
30 minutes. The episodes lasted 1-5 minutes (10 dogs; 53%),
5-10 minutes (4 dogs; 21%), 10-30 minutes (3 dogs; 16%), or >30 minutes
(2 dogs; 10%). Overall, episodes ranged from 1-90 minutes, with a median
time of 4.5 minutes.
3.3 | Diagnostic evaluation
General physical and neurological examinations, CBC, and serum
biochemistry profile were unremarkable in all 19 dogs. Magnetic reso-
nance imaging of the brain and CSF analysis were performed in 2 dogs
(10%), and electrodiagnostic examination (electromyography, motor
nerve conduction velocity and repetitive nerve stimulation) were per-
formed in 1 dog (5%) and all were unremarkable. Three dogs (16%)
tested negative for the PIGN mutation.10
3.4 | Clinical course, treatment, and outcome
Acetazolamide at a dosage of 4 mg/kg PO q12h or q8h was initiated
in 6 dogs (32%). The episodes decreased in frequency in 4 dogs (21%),
but none of the dogs became episode-free. In 2 dogs (10%) treated
with acetazolamide, no improvement was seen and 1 of them
experienced severe adverse effects, including apathy and drowsiness.
Acetazolamide was discontinued in both dogs and they were treated
with fluoxetine at a dosage of 2 mg/kg PO q24h. One dog became
episode-free after treatment with fluoxetine, and the other dog's epi-
sode frequency did not change and it was presented for evaluation of
loss of appetite, possibly caused by the medication. This dog recently
was given a gluten-free diet, but no improvement was seen. Dietary
changes (gluten-free diet) were made in 7 dogs (37%), and 6 of them
became episode-free after instituting the new diet. In 1 dog that
received a gluten-free diet, episode frequency remained the same but
the duration of individual episodes decreased. In 6 dogs (32%), no diet
or medication was given. In 4 of these dogs, the episodes stopped
spontaneously and in 2 the episodes continued at the same frequency.
Of the 7 dogs that had concomitant health issues at the time the
episodes started, only 1 was treated with a gluten-free diet. This
patient was showing episodes of vomiting and borborygmi, which
resolved after the new diet was started as primary treatment for
the PD.
4 | DISCUSSION
At the Small Animal Teaching Hospital at Ghent University, paroxys-
mal movement disorders have been diagnosed clinically in various
breeds, but our results seem to indicate that the Maltese breed is
over-represented. We are not aware of any other reported cases
other than those reported by our group. The high number of Maltese
dogs with PD in our region might suggest a genetic or familial compo-
nent, although this remains to be proven. Unfortunately, none of the
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Maltese dogs in our study had pedigrees, which precluded any pedigree
analysis. Our aim was to describe the clinical features of a PD in Maltese
dogs and to describe its clinical course, treatment, and outcome.
Most dogs previously reported with PD have a mean age of onset
of <1 year,4,19,25-28 but it could vary from 2 to 4 years in a few
reports.5,7,8,9,14,18,29,30 On the contrary, the mean age of the first
experienced episode in our Maltese dogs was higher (mean, 5.4 years;
range, 1-11 years).
Paroxysmal dyskinesia affecting Maltese dogs resembles PNKD in
humans, where the episodes are defined as attacks of involuntary
movements that occur spontaneously.11 In 42% of our dogs, the epi-
sodes occurred randomly (after stress or exercise or both or at rest).
In 26% of the cases, the episodes started only after stress or exercise.
Stress (42%) and exercise (23%) also have been associated as a trigger
in a group of Norwich Terriers.7 Contrary to dyskinesias observed in a
group of Border Terriers in which the episodes occurred mainly at rest
for the majority of the dogs (87%),30 in our study the episodes
occurred during rest or sleep only in 6 Maltese dogs (32%). Two Mal-
tese dogs experienced an episode during the neurological examina-
tion, possibly as a result of stress. In other dogs with PD, owners
could predict an episode because their dogs would seek their atten-
tion before an episode,3,9 as was seen in 8 dogs (42%) in our study. As
described in humans with PNKD, patients are able to report an aura-
like sensation immediately before an episode, characterized by limb
stiffness or paresthesia or an undefined feeling.31 Dogs might have a
similar sensation, which could explain why they would seek the atten-
tion of the owner before an episode occurs. As reported in other breeds
with PD, all affected Maltese dogs in our study remained conscious dur-
ing the episodes, which could not be stopped even when the dog was
stimulated by physical or vocal prompting by the owners. Although the
episodes could not be interrupted, the preservation of consciousness
during the generalized episodes, despite motor manifestations in all
4 limbs, is supportive of a diagnosis of PD. For this reason, a movement
disorder would be considered more likely than a generalized tonic-
clonic seizure.1,3 Paroxysmal dyskinesias also are differentiated from
focal epileptic seizures by a lack of seizure activity on ictal electroen-
cephalography (EEG), which is the ideal method to distinguish both con-
ditions.2,11 None of the Maltese dogs in our study underwent EEG
during an episode because only 2 dogs had unexpected episodes during
consultation. Interictal EEG might have been useful in our dogs, because
we would expect no epileptic seizure activity on EEG. In humans, inter-
ictal scalp EEG is used routinely to record the electrical signals of the
brain and is considered an effective method for defining the epilepto-
genic zone32 in approximately 70% of patients with epileptic seizure
activity.33 In veterinary medicine, ictal or interictal EEG presents logisti-
cal and technical limitations,2,7 because of the low likelihood of wit-
nessing an event3 and limited availability of equipment.27 Even when
feasible, interpretation of ictal EEG might be challenging in dogs pre-
senting with PD because muscle activity may cause artifacts.6
Five Maltese dogs (26%) presented with salivation, vomiting, or
both during the episodes. Although affected animals do not usually
exhibit autonomic dysfunction,1,4 a recent study reported abnormal
autonomic activity during episodes of PD in Border Terriers in 56% of
the cases, most commonly hypersalivation and vomiting in 48 and
24% of the affected dogs, respectively.30 Furthermore, autonomic
signs also have been reported in other studies.6,9 In 2 previous
reports,2,3 dogs presumably diagnosed with PD that showed auto-
nomic signs were excluded from the study. Consequently, autonomic
abnormalities might be more common than originally thought during
PD events. Presence of autonomic signs has been reported to be a
factor that can be used to distinguish PDs from epileptic seizures,2,4,29
but based on what was observed in our study and described in the
veterinary literature, this distinction might not be helpful anymore.
Furthermore, we cannot necessarily conclude that these clinical signs
in the 5 Maltese dogs are abnormal autonomic signs and not a conse-
quence of a possible multisystem disorder, as seen in PD in Border
Terriers.8
In our study, the episodes mainly were characterized by sudden dysto-
nia (sustainedmuscle contraction producing abnormal movements and pos-
tures) affecting !1 limbs, the trunk and the head. Such clinical signs have
been reported in other breeds, includingNorwich Terriers,7 Bichon Frises,29
Yorkshire Terriers,27 Golden Retrievers,19 Border Terriers,3 Chinook dogs,2
Jack Russel Terriers, and Labrador Retrievers.18 In general, dogs diagnosed
with PD tend to have an episode duration <5 minutes,7,18,28,30 which was
the case in 10Maltese dogs (53%) in our study.
The underlying mechanism of PD remains unknown, and its
diagnosis is speculative in many cases.7,18 Similar to dogs with idio-
pathic epilepsy, dogs with PD are clinically and neurologically normal
between episodes, and thus structural intracranial pathology seems
unlikely.3,27,29,30 Clinicians should take this likelihood into account
when choosing the most cost efficient diagnostic approach.
Initially, patients diagnosed with PD were treated with acetazol-
amide, based on evidence in the current veterinary literature.19 Recently,
the benefits of a gluten-free diet in dogs with PD have become more
established.9,14 Acetazolamide also might have beneficial effects as was
observed in a previous report.19 The majority of the dogs in our study
treated with acetazolamide experienced a decrease in episode frequency.
Acetazolamide is a carbonic anhydrase inhibitor that results in kaliuresis,
diuresis, and metabolic acidosis and also lowers serum bicarbonate con-
centrations, which decreases the amount of brain lactate and pyruvate,
resulting in brain acidosis and changes in intracellular and extracellular
pH.34 The change in pH in the brain parenchyma alters the membrane
potential, culminating in a decreased neuronal excitability.35 The suppres-
sive effect on neuronal excitability is the main mechanism of action in
humans with PD.36 Six dogs that were fed a gluten-free diet became
episode-free. The benefits of a gluten-free diet already have been
observed in other breeds with PD.3,7,9,26 Some of the Maltese dogs in
our study were presented with signs of gastrointestinal disease, skin
allergy, or both. These signs also were seen in Border Terriers diag-
nosed with gluten-sensitivePD,8,14,30 in which serological markers of
gluten sensitivity (anti-transglutaminase-2 and anti-gliadin antibodies)
were detected in affected dogs. These titers decreased after a gluten-
free diet was initiated. Because the majority of our Maltese dogs that
received a gluten-free diet responded well to dietary change, future
research should focus on a possible relation between serological markers
of gluten sensitivity and Maltese dogs with PD. Also, the effect of a
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gluten-free diet on concomitant signs such as gastrointestinal disease or
skin problems warrants further investigation. Spontaneous remission
occurred in 21% of the affected Maltese dogs (n = 4), a similar percent-
age compared to other breeds previously described.18 Although most
dogs seem to respond positively to the different types of treatments
offered, it is important to emphasize the possible natural course of this
condition and the so-called placebo phenomenon reported for epilepsy
drug treatment trials.37 It has been observed previously that episodes
have a tendency to stabilize in the first few years after the beginning of
clinical signs, at which point they may improve in most cases and resolve
completely in a few cases.18 Therefore, the natural course of PD in
untreated dogs should be considered before attributing remission to spe-
cific treatment effects.18
Our study had some limitations. A complete diagnostic evaluation
was not performed in all patients, including electrodiagnostic studies
(EEG), MRI, and CSF analysis. In addition, a detailed pedigree or
recorded ancestry together with further genetic investigation could
have added evidence to our conclusions. The retrospective character
of our study, use of data obtained from a questionnaire and the fact
that most of the episodes were identified through video footage also
were limitations. To investigate the effect of dietary or medical treat-
ment, a double-blinded randomized placebo-controlled trial would
have been more appropriate before drawing definitive conclusions.
The finding of a paroxysmal movement disorder with characteris-
tics specific for a single breed is highly suggestive for a genetic predis-
position. Future research should focus on elucidating the genetic basis
of PD in Maltese dogs because doing so may promote understanding
of the pathophysiology and improve treatment.
5 | CONCLUSION
A PD, which resembles PNKD in humans, has been characterized
phenotypically in Maltese dogs. Given the breed predisposition and
regional distribution of the disease, a genetic basis is likely. Overall,
disease progression is variable and, regardless the treatment used,
prognosis appears fair to good. Interestingly, several cases in our
study population experienced spontaneous clinical remission with-
out any treatment.
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